88 related articles for article (PubMed ID: 19887481)
21. Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.
Gamboa EO; Rehmus EH; Haller N
Clin Colorectal Cancer; 2010 Jan; 9(1):55-8. PubMed ID: 20100690
[TBL] [Abstract][Full Text] [Related]
22. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
[TBL] [Abstract][Full Text] [Related]
23. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ
J Clin Oncol; 2010 Jul; 28(19):3191-8. PubMed ID: 20516443
[TBL] [Abstract][Full Text] [Related]
25. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
26. Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
Gunnlaugsson A; Anderson H; Fernebro E; Kjellén E; Byström P; Berglund K; Ekelund M; Påhlman L; Holm T; Glimelius B; Johnsson A
Eur J Cancer; 2009 Mar; 45(5):807-13. PubMed ID: 19110416
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
[TBL] [Abstract][Full Text] [Related]
28. [Significance of CEA to predict the effect of chemotherapy with bevacizumab].
Sasaki S; Ishimaru M; Suzuki H; Ogawa M; Sato Y
Gan To Kagaku Ryoho; 2010 Mar; 37(3):463-7. PubMed ID: 20332684
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab.
Goyal S; Rao MS; Khan A; Huzzy L; Green C; Haffty BG
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):408-13. PubMed ID: 20452134
[TBL] [Abstract][Full Text] [Related]
30. Chemorefractory rhabdomyosarcoma treated with radiotherapy, bevacizumab, statins and surgery and maintenance with bevacizumab and chemotherapy.
Lindén O; Greiff L; Wahlberg P; Vinge E; Kjellén E
Onkologie; 2008 Jul; 31(7):391-3. PubMed ID: 18596387
[TBL] [Abstract][Full Text] [Related]
31. Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging.
Koukourakis MI; Mavanis I; Kouklakis G; Pitiakoudis M; Minopoulos G; Manolas C; Simopoulos C
Am J Clin Oncol; 2007 Jun; 30(3):315-8. PubMed ID: 17551312
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated radiotherapy with 5-fluorouracil radiosensitization for locally "far advanced" breast cancer.
Kosma L; Koukourakis M; Skarlatos J; Zambatis C; Ardavanis A; Beroukas K; Yannakakis D
Am J Clin Oncol; 1997 Dec; 20(6):562-6. PubMed ID: 9391540
[TBL] [Abstract][Full Text] [Related]
33. Tracheal Diverticulum Following Paratracheal Hypofractionated Radiotherapy in the Setting of Prior and Subsequent Bevacizumab.
Chaudhuri AA; Chen JJ; Carter JN; Binkley MS; Kumar KA; Dudley SA; Sung AW; Loo BW
Cureus; 2016 Apr; 8(4):e578. PubMed ID: 27226939
[TBL] [Abstract][Full Text] [Related]
34. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
George TJ; Franke AJ; Chakravarthy AB; Das P; Dasari A; El-Rayes BF; Hong TS; Kinsella TJ; Landry JC; Lee JJ; Monjazeb AM; Jacobs SA; Raben D; Rahma OE; Williams TM; Wu C; Coleman CN; Vikram B; Ahmed MM
Cancer; 2019 Aug; 125(16):2732-2746. PubMed ID: 31017664
[TBL] [Abstract][Full Text] [Related]
35. The radiosensitizing effect of doranidazole on human colorectal cancer cells exposed to high doses of irradiation.
Zhang L; Gong A; Ji J; Wu Y; Zhu X; Lv S; Lv H; Sun X
BMC Cancer; 2007 Oct; 7():188. PubMed ID: 17919337
[TBL] [Abstract][Full Text] [Related]
36. Patterns of prescribing radiotherapy and bevacizumab in nationwide practice - analysis of 101 designated cancer care hospitals in Japan.
Tsukada Y; Nakamura F; Iwamoto M; Terahara A; Higashi T
J Radiat Res; 2016 Mar; 57(2):157-63. PubMed ID: 26661853
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II).
Ogawa Y; Kubota K; Ue H; Kataoka Y; Tadokoro M; Miyatake K; Tsuzuki K; Yamanishi T; Itoh S; Hitomi J; Hamada N; Kariya S; Fukumoto M; Nishioka A; Inomata T
Int J Oncol; 2009 Mar; 34(3):609-18. PubMed ID: 19212665
[TBL] [Abstract][Full Text] [Related]
38. Concurrent hypofractionated radiotherapy and 5-Fluorouracil for advanced sarcomas of the bone.
Zambatis C; Skarlatos J; Koukourakis M; Kosma L; Giatromanolaki A; Beroukas K; Yannakakis D
Sarcoma; 1998; 2(1):25-8. PubMed ID: 18521229
[TBL] [Abstract][Full Text] [Related]
39. Pirarubicin pasting for radiotherapy of inoperable colorectal cancers.
Okuyama S; Sato A
Tohoku J Exp Med; 1996 Jul; 179(3):223-6. PubMed ID: 8888512
[TBL] [Abstract][Full Text] [Related]
40. [Increasing the effectiveness of skin cancer T(2-3) N0M0 radiotherapy by use of radiosencibilizers].
Poliakov PIu; Bychenkov OA; Oltarzhevskaia ND; Shumskiĭ VI; Rogatkin DA
Vestn Ross Akad Med Nauk; 2005; (5):47-51. PubMed ID: 15960206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
